Summary of Purpose
This is a randomized, triple-blind, placebo-controlled, multicenter clinical trial. investigators plan to enroll 774 eligible patients, which will be randomized into either the butylphthalide (NBP) or placebo group in a 2:1 ratio.The main purpose of this study is to determine whether butylphthalide can improve dynamic Cerebral Autoregulation (dCA) in large-artery atherosclerosis acute ischemic stroke.Read More →
The following dates are available for this trial. Trial information last updated on 11 April 2018.
|28 Feb 2018||18 Jan 2018||1 Feb 2020||1 Jul 2020||1 Apr 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Yi Yang Lead
- Yi Yang, MD, PhD
- Zhenni Guo, MD